| Small cell carcinoma |
Treatment |
n (%) |
Treatment |
n (%) |
Treatment |
n (%) |
| Etoposide, Carboplatin |
47 (60.3) |
Etoposide, Carboplatin |
43 (42.2) |
Etoposide, Carboplatin |
6 (17.6) |
| Etoposide, Cisplatin |
18 (23.1) |
Paclitaxel, Nedaplatin |
13 (12.7) |
Irinotecan |
6 (17.6) |
| Etoposide |
5 (6.4) |
Paclitaxel, Carboplatin |
12 (11.8) |
Paclitaxel, Carboplatin |
5 (14.7) |
| Lobaplatin, Semustine, Etoposide |
2 (2.6) |
Etoposide, Cisplatin |
11 (10.8) |
Docetaxel |
3 (8.8) |
| Paclitaxel |
2 (2.6) |
Paclitaxel |
8 (7.8) |
Nedaplatin, Ifosfamide |
3 (8.8) |
| Paclitaxel, Carboplatin |
2 (2.6) |
Weekly Irinotecan |
7 (6.8) |
Paclitaxel, Nedaplatin |
3 (8.8) |
| Paclitaxel, Nedaplatin |
2 (2.6) |
Etoposide |
4 (3.9) |
Etoposide |
2 (5.9) |
| - |
- |
Carboplatin, Abraxane |
2 (2.0) |
Etoposide, Cisplatin |
2 (5.9) |
| - |
- |
Nedaplatin, Etoposide |
2 (2.0) |
Irinotecan, Cisplatin |
2 (5.9) |
| - |
- |
- |
- |
Paclitaxel, Nedaplatin, Endostatin |
2 (5.9) |
|
First-line (N = 120)
|
Second-line (N = 126)
|
Third-line (N = 48)
|
|
Treatment |
n (%) |
Treatment |
n (%) |
Treatment |
n (%) |
| Squamous cell carcinoma |
Nedaplatin, Docetaxel |
35 (27.8) |
Nedaplatin, Docetaxel |
42 (18.6) |
Docetaxel |
15 (18.1) |
| Gemcitabine, Carboplatin |
24 (19.0) |
Docetaxel |
33 (14.6) |
Nedaplatin, Docetaxel |
15 (18.1) |
| Docetaxel, Cisplatin |
21 (16.7) |
Gemcitabine, Carboplatin |
24 (10.6) |
Vinorelbine, Gemcitabine |
14 (16.9) |
| Gemcitabine, Cisplatin |
21 (16.7) |
Docetaxel, Cisplatin |
23 (10.2) |
S1 (tegafur, gimeracil, and oteracil) |
8 (9.6) |
| Docetaxel |
13 (10.3) |
Vinorelbine, Gemcitabine |
31 (13.7) |
Vinorelbine, Nedaplatin |
5 (6.0) |
| Paclitaxel, Carboplatin |
7 (5.6) |
Gemcitabine |
19 (8.4) |
Erlotinib |
4 (4.8) |
| Vinorelbine, Carboplatin |
5 (4.0) |
Gemcitabine, Cisplatin |
13 (5.8) |
Gemcitabine |
3 (3.6) |
| – |
– |
Nedaplatin, Gemcitabine |
13 (5.8) |
Gemcitabine, Carboplatin |
3 (3.6) |
| – |
– |
S1 (tegafur, gimeracil, and oteracil) |
7 (3.1) |
Nedaplatin, S1 (tegafur, gimeracil, and oteracil) |
3 (3.6) |
| – |
– |
Paclitaxel, Carboplatin |
5 (2.2) |
Pemetrexed |
3 (3.6) |
| – |
– |
Erlotinib |
5 (2.2) |
Abraxane |
2 (2.4) |
|
|
Vinorelbine, Carboplatin |
5 (2.2) |
Docetaxel, Cisplatin |
2 (2.4) |
| – |
– |
Abraxane |
3 (1.3) |
Nedaplatin, Gemcitabine |
2 (2.4) |
| – |
– |
Paclitaxel |
3 (1.3) |
Pemetrexed, Nedaplatin |
2 (2.4) |
| – |
– |
– |
– |
Vinorelbine |
2 (2.4) |
|
First-line (N = 333)
|
Second-line (N = 399)
|
Third-line (N = 176)
|
|
Treatment |
n (%) |
Treatment |
n (%) |
Treatment |
n (%) |
| Adenocarcinoma |
Pemetrexed, Carboplatin |
94 (28.2) |
Pemetrexed, Carboplatin |
131 (18.5) |
Docetaxel |
61 (20.4) |
| Gemcitabine, Carboplatin |
89 (26.7) |
Pemetrexed |
110 (15.5) |
Pemetrexed |
47 (15.7) |
| Gemcitabine, Cisplatin |
35 (10.5) |
Docetaxel |
71 (10.0) |
Pemetrexed, Carboplatin |
33 (11.0) |
| Pemetrexed |
32 (9.6) |
Gemcitabine, Carboplatin |
70 (9.9) |
Vinorelbine, Gemcitabine |
20 (6.6) |
| Pemetrexed, Cisplatin |
29 (8.7) |
Gefitinib |
64 (9.0) |
Icotinib |
19 (6.4) |
| Vinorelbine, Carboplatin |
27 (8.1) |
Nedaplatin, Docetaxel |
32 (4.5) |
Gefitinib |
18 (6.0) |
| Gemcitabine |
21 (6.3) |
Icotinib |
31 (4.4) |
Erlotinib |
17 (5.7) |
| Paclitaxel, Carboplatin |
21 (6.3) |
Erlotinib |
30 (4.2) |
Gemcitabine, Carboplatin |
13 (4.3) |
| Gefitinib |
16 (4.8) |
Gemcitabine |
28 (4.0) |
S1 (tegafur, gimeracil, and oteracil) |
13 (4.3) |
| Vinorelbine, Cisplatin |
16 (4.8) |
Pemetrexed, Cisplatin |
28 (4.0) |
Nedaplatin, Docetaxel |
11 (3.7) |
| Docetaxel |
10 (3.0) |
Gemcitabine, Cisplatin |
22 (3.1) |
Pemetrexed, Nedaplatin |
10 (3.3) |
| Pemetrexed, Nedaplatin |
9 (2.7) |
Pemetrexed, Nedaplatin |
16 (2.3) |
Gemcitabine |
8 (2.7) |
| Docetaxel, Carboplatin |
8 (2.4) |
Paclitaxel, Carboplatin |
15 (2.1) |
Pemetrexed, Oxaliplatin |
8 (2.7) |
| Icotinib |
7 (2.1) |
Vinorelbine, Carboplatin |
15 (2.1) |
Crizotinib |
5 (1.7) |
| – |
– |
Pemetrexed, Oxaliplatin |
11 (1.6) |
Docetaxel, Cisplatin |
5 (1.7) |
| – |
– |
Docetaxel, Cisplatin |
10 (1.4) |
Pemetrexed, Cisplatin |
5 (1.7) |
| – |
– |
Docetaxel, Carboplatin |
8 (1.1) |
Afatinib |
3 (1.0) |
| – |
– |
S1 (tegafur, gimeracil, and oteracil) |
8 (1.1) |
Bevacizumab |
3 (1.0) |
| – |
– |
Vinorelbine, Gemcitabine |
8 (1.1) |
– |
– |
